Bitmine projects it will generate $334 million in annual revenue from staking activities based on its $15.8 billion cryptocurrency treasury. This forecast highlights the growing profitability of staking in the crypto sector, where digital assets are locked to support network operations and earn rewards. The sizable treasury indicates Bitmine's significant position in the market, potentially attracting more investors interested in staking returns. This development underscores the increasing importance of staking as a revenue stream in the evolving crypto economy.
The Ethereum and Base Wallet standards collaboration breakdown provides context for cryptocurrency market activity. For readers following crypto assets, here is Pluang's market snapshot as of Sep 15, 2026 16:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 17 rose and 32 fell. Notable movements include COTI rising 8.03% to Rp307 with a typical hold time of 121 days and Pluang order activity showing 76% Sell / 24% Buy; VET dropping 6.99% to Rp131 with a 146-day hold time and 99% Sell / 1% Buy order activity; and XTZ down 6.41% to Rp4,626 with a 100-day hold time and 57% Sell / 43% Buy order activity.
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
In early November, Sui will unlock a tranche of tokens ranging from 2.07 million to 22.6 million SUI, representing up to 0.55% of the circulating supply. This unlock is part of a long-term vesting schedule with a 12-month cliff and 72 months of linea...
Early Ethereum investors sold a total of 4,000 ETH from two wallets, with one ICO participant selling 1,000 ETH and another holder offloading 3,000 ETH worth $7.23 million. This activity coincides with Santiment's report of the largest daily net ETH ...
Immatics presented encouraging clinical data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapies at the 2026 ESMO Annual Meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in advanced melanoma patients with high PRAM...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
